Robert Shaffer, MD
Gastroenterology · Birmingham, ALNPI 1528002151
Payments from drug & device makers
Across 1,392 payments — averaging $860.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$339K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$170K
- Phathom Pharmaceuticals, Inc.$162K
- Regeneron Healthcare Solutions, Inc.$138K
- Genentech, Inc.$130K
- AbbVie$93K
- plus $164K from 30 others
What the payments were for
- Consulting fees$24,0642%
- Speaking & faculty fees$879,35285%
- Travel & lodging$101,78910%
- Food & beverage$27,2413%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 274 | $339,423 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 282 | $169,902 |
| Phathom Pharmaceuticals, Inc. | 151 | $162,436 |
| Regeneron Healthcare Solutions, Inc. | 119 | $137,913 |
| Genentech, Inc. | 40 | $130,223 |
| AbbVie(2 entities) | 187 | $92,939 |
| E.r. Squibb & Sons, L.L.C. | 35 | $41,847 |
| Madrigal Pharmaceuticals | 34 | $40,674 |
| Lilly USA, LLC | 43 | $39,468 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $13,523 |
| Ipsen Biopharmaceuticals, Inc | 16 | $12,392 |
| Celltrion USA Inc. | 15 | $5,491 |
| Eli Lilly | 1 | $3,750 |
| Bristol Myers Squibb | 19 | $3,093 |
| Romark Laboratories, LC | 14 | $1,450 |
| Johnson & Johnson | 42 | $868 |
| Pfizer | 25 | $498 |
| Ironwood Pharmaceuticals, Inc | 13 | $376 |
| Gilead | 9 | $273 |
| Ardelyx, Inc. | 7 | $136 |
| QOL Medical, LLC | 5 | $124 |
| Mallinckrodt Hospital Products Inc. | 3 | $90 |
| Evoke Pharma, Inc. | 4 | $85 |
| Braintree Laboratories, Inc. | 4 | $52 |
| Janssen Scientific Affairs, LLC | 1 | $47 |
| Intercept Pharmaceuticals, Inc. | 2 | $38 |
| Merck | 2 | $31 |
| Shire North American Group Inc | 2 | $30 |
| UCB, Inc. | 2 | $28 |
| Orphalan Inc | 1 | $25 |
| Amgen | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Axonics, Inc. | 1 | $17 |
| Intra-sana Laboratories | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,197,327 in reported general payments places this provider in the 95th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 24 | $667,400 |
| OcalivaObeticholic Acid | 18 | $167,470 |
| Humira PenAdalimumab | 15 | $97,191 |
| ZenpepLipase/Protease/Amylase | 12 | $75,512 |
| LinzessLinaclotide | 93 | $73,869 |
| CreonLipase/Protease/Amylase | 33 | $73,376 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 167 | $26,548 |
| MotegrityPrucalopride Succinate | 27 | $19,267 |
| Dexlansoprazole DrDexlansoprazole | 36 | $11,559 |
| Mesalamine ErMesalamine | 44 | $10,143 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 135 | $7,986 |
| Pantoprazole Sodium | 537 | $6,720 |
| Mesalamine | 11 | $5,575 |
| Famotidine | 206 | $3,141 |
| Ursodiol | 24 | $3,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $868 | $667,40024 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $38 | $167,47018 claims |
| AbbVieLinzess, Creon | $92,939 | $147,245126 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $52 | $27,902178 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $13,523 | $19,26727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Birmingham
- Meagan GrayBirmingham$600K
- Kondal Kyanam Kabir BaigBirmingham$324K
- Mukul MehraBirmingham$193K
- David SteeleBirmingham$183K
- Omar MassoudBirmingham$147K
- Sujan RaviBirmingham$137K
- Kirk RussBirmingham$135K
- James CallawayBirmingham$77K
- Raymond TobiasBirmingham$58K
- Shajan PeterBirmingham$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.